1. Home
  2. DNUT vs ARVN Comparison

DNUT vs ARVN Comparison

Compare DNUT & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Krispy Kreme Inc.

DNUT

Krispy Kreme Inc.

HOLD

Current Price

$3.04

Market Cap

577.8M

ML Signal

HOLD

Logo Arvinas Inc.

ARVN

Arvinas Inc.

HOLD

Current Price

$7.84

Market Cap

600.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DNUT
ARVN
Founded
1937
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Food Chains
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
577.8M
600.2M
IPO Year
2021
2018

Fundamental Metrics

Financial Performance
Metric
DNUT
ARVN
Price
$3.04
$7.84
Analyst Decision
Hold
Buy
Analyst Count
5
19
Target Price
$4.15
$15.05
AVG Volume (30 Days)
2.0M
694.4K
Earning Date
05-07-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
58.84
EPS
N/A
1.70
Revenue
$1,522,616,000.00
$262,600,000.00
Revenue This Year
$0.55
N/A
Revenue Next Year
$3.59
N/A
P/E Ratio
N/A
$5.01
Revenue Growth
N/A
N/A
52 Week Low
$2.88
$6.97
52 Week High
$5.11
$14.22

Technical Indicators

Market Signals
Indicator
DNUT
ARVN
Relative Strength Index (RSI) N/A N/A
Support Level N/A N/A
Resistance Level N/A N/A
Average True Range (ATR) 0.00 0.00
MACD 0.00 0.00
Stochastic Oscillator 0.00 0.00

Price Performance

Historical Comparison
DNUT
ARVN

About DNUT Krispy Kreme Inc.

Krispy Kreme Inc is a sweet-treat brand company. The company's Original Glazed doughnut is recognized for its hot-off-the-line, melt-in-mouth experience. It operates through its network of fresh Doughnut Shops, partnerships with retailers, and a growing e-commerce and delivery business. The company conducts its business through the following three reported segments: U.S., which includes all operations in the United States; International, which includes operations in the U.K., Ireland, Australia, New Zealand, Canada, Japan, and Mexico; and Market Development, which includes franchise operations world-wide. It derives maximum revenue from the U.S. segment.

About ARVN Arvinas Inc.

Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.

Share on Social Networks: